phentermine has been researched along with Prediabetic State in 2 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
Prediabetic State: The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline." | 9.19 | Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. ( Bohannon, NJ; Day, WW; Garvey, WT; Henry, R; Ryan, DH; Schwiers, M; Toplak, H; Troupin, B, 2014) |
| "OBJECTIVE To evaluate over 108 weeks the effect of phentermine and topiramate extended release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with prediabetes and/or metabolic syndrome (MetS) at baseline." | 5.19 | Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. ( Bohannon, NJ; Day, WW; Garvey, WT; Henry, R; Ryan, DH; Schwiers, M; Toplak, H; Troupin, B, 2014) |
| " Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine." | 4.83 | Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. ( Pi-Sunyer, FX, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garvey, WT | 1 |
| Ryan, DH | 1 |
| Henry, R | 1 |
| Bohannon, NJ | 1 |
| Toplak, H | 1 |
| Schwiers, M | 1 |
| Troupin, B | 1 |
| Day, WW | 1 |
| Pi-Sunyer, FX | 1 |
1 review available for phentermine and Prediabetic State
| Article | Year |
|---|---|
Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors.
Topics: Caloric Restriction; Cardiovascular Diseases; Cyclobutanes; Diabetes Mellitus; Diet; Diet, Fat-Restr | 2006 |
1 trial available for phentermine and Prediabetic State
| Article | Year |
|---|---|
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release.
Topics: Anti-Obesity Agents; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Fructose; Human | 2014 |